Agitation: Clinical Trials

11 trials for Agitation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Completed 11
Phase 24Completed 4

Follow Agitation: new trials by email Literature Review of Agitation trials Research Report on Agitation

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
AXS-05, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Phase 3CompletedAxsome Therapeutics, Inc.4082022-09-062026-08-13
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
BXCL501, Matching Placebo - Agitation, Dementia
Phase 3CompletedBioXcel Therapeutics Inc1512022-04-272026-08-11
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
Sublingual film containing dexmedetomidine (BXCL501), Placebo Film - Agitation, Schizophrenia
Phase 3CompletedBioXcel Therapeutics Inc3802020-01-242026-08-11
Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)
Dexmedetomidine, Placebo - Delirium, Agitation
Phase 3CompletedUniversity Hospital, Clermont-Ferrand1682017-12-212026-05-13
Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children
Dexmedetomidine, saline - Agitation
Phase 2 / Phase 3CompletedAssiut University902016-05-012020-07-14
Safety and Efficacy of Nabilone in Alzheimer's Disease
Nabilone, Placebo - Alzheimer Disease, Agitation
Phase 2 / Phase 3CompletedSunnybrook Health Sciences Centre382015-01-012020-06-25
Pain in Patients With Dementia and Behavioural Disturbances
Paracetamol, Morphine, Buprenorphine plaster - Dementia, Pain
Phase 2 / Phase 3CompletedUniversity of Bergen3522009-11-012011-08-10
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
Dexmedetomidine, Saline - Agitation, Anesthesia
Phase 3CompletedSt. Luke's-Roosevelt Hospital Center332009-08-012018-11-27
Citalopram for Agitation in Alzheimer's Disease
citalopram, placebo - Alzheimer's Disease, Agitation
Phase 3CompletedJHSPH Center for Clinical Trials1862009-07-012014-06-27
A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia
Intramuscular Haloperidol, Intramuscular Levosulpiride - Agitation
Phase 2 / Phase 3CompletedShanghai Mental Health Center2402009-02-012010-12-03
Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
IM olanzapine, IM haloperidol plus lorazepam - Schizophrenia, Schizoaffective Disorder
Phase 3CompletedNational Taiwan University Hospital672006-07-012014-09-15

Narrower conditions

Psychomotor Agitation (11)  ·  Alzheimer Disease (3)  ·  Schizophrenia (3)  ·  Dementia (2)  ·  Pain (2)  ·  Psychotic Disorders (2)  ·  Aggression (1)  ·  Agnosia (1)  ·  Delirium (1)  ·  Emergence Delirium (1)  ·  Weight Loss (1)

Broader conditions

Aberrant Motor Behavior in Dementia (11)  ·  Behavior (11)  ·  Behavioral Symptoms (11)  ·  Dyskinesias (11)  ·  Nervous System Diseases (11)  ·  Neurobehavioral Manifestations (11)  ·  Neurologic Manifestations (11)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Psychomotor Disorders (11)  ·  Signs and Symptoms (11)  ·  Mental Disorders (10)  ·  Neurocognitive Disorders (7)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Dementia (3)

Interventions

Dexmedetomidine (5)  ·  Sodium Chloride (2)  ·  Acetaminophen (1)  ·  Citalopram (1)  ·  Haloperidol (1)  ·  Lorazepam (1)  ·  Morphine (1)  ·  Olanzapine (1)  ·  Pregabalin (1)  ·  Saline Solution (1)  ·  nabilone (1)

Sponsors

BioXcel Therapeutics Inc (2)  ·  Assiut University (1)  ·  Axsome Therapeutics, Inc. (1)  ·  JHSPH Center for Clinical Trials (1)  ·  National Taiwan University Hospital (1)  ·  Shanghai Mental Health Center (1)  ·  St. Luke's-Roosevelt Hospital Center (1)  ·  Sunnybrook Health Sciences Centre (1)  ·  University Hospital, Clermont-Ferrand (1)  ·  University of Bergen (1)

Countries

United States (5)  ·  Canada (2)  ·  China (1)  ·  Egypt (1)  ·  France (1)  ·  Norway (1)  ·  Puerto Rico (1)  ·  Taiwan (1)

Top investigators

BioXcel MM, MD (2)  ·  Anton Porsteinsson, MD (1)  ·  Bettina S. Husebo, MD, PhD (1)  ·  Bruce Pollock, MD (1)  ·  Clive Ballard, MD, PhD (1)  ·  Constantine Lyketsos, MD, MHS (1)  ·  Dag Aarsland, MD, Phd (1)  ·  Daniel Weintraub, MD (1)  ·  Davengere Devanand, MD (1)  ·  David Shade, Esq (1)  ·  Huafang LI, MD,PhD (1)  ·  Jacobo Mintzer, MD (1)  ·  Jerome Yesavage, MD (1)  ·  Jolie Narang, M.D. (1)

Results publications

PMID 21765198, PMID 23611363, PMID 24549548, PMID 24806873, PMID 24914549, PMID 25791540, PMID 27247487, PMID 27524403, PMID 29136228, PMID 29866205, PMID 30753761, PMID 31182351, PMID 31322567, PMID 31547752, PMID 31672419, PMID 34532852, PMID 36002761, PMID 36198061, PMID 41160116

NIH funding

2008 (1), 2017 (1), R01AG031348 (1)